NBIX

As of 2026-09-11, NBIX scores 52out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. NBIX trades at $156.57, 11% below the band floor.

NBIX scores 52 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 52. Its strongest factor is value at 77 (strong), where it screens cheap on the model's valuation inputs, followed by quality at 58. The weakest is momentum at 43, where price trend is the soft spot. Among Healthcare stocks it ranks in roughly the top 20% of the Healthcare names the model scores.

On valuation, NBIX is priced near the floor of its own recent range — the cheap end on the model's valuation read. The blended composite before the macro overlay was 55. Same-sector names the model rates nearby include HALO, HNGE, THC.

This is a descriptive factor read on NBIX, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where NBIX sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for NBIX runs $174.99–$245.49. Current price $156.57 sits 11% below the band floor. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.